Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults who are Virologically Suppressed

Trial Profile

A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults who are Virologically Suppressed

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabotegravir+rilpivirine (Primary) ; Cabotegravir; Rilpivirine
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ATLAS-2M
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 22 Aug 2019 Primary endpoint has been met. (Percentage of subjects with plasma HIV ribonucleic acid (RNA) 50 copies per milliliter (copies/mL) at Week 48), as reported in a ViiV Healthcare Media Release.
    • 22 Aug 2019 According to a ViiV Healthcare media release, detailed results from the study will be presented at an upcoming scientific meeting.
    • 22 Aug 2019 According to a ViiV Healthcare media release, the company announced results with Pfizer Inc. and Shionogi Limited as shareholders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top